2020 BIO Investor Forum Buzz of BIO Finalist
Starton is a clinical-stage biotechnology company transforming approved drugs for novel indications. Our initial focus is in hematological malignancies using a continuous delivery platform. Its blockbuster program, STAR-LLD is entering Phase 1/2 development for multiple new indications in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
The STAR-LLD program has already displayed unprecedented efficacy results in a murine multiple myeloma model. The STAR-LLD continuous infusion displayed superior efficacy versus lenalidomide standard of care: tumor volume increase at day 29 was 483% with standard of care versus an -81% reduction in tumor volume in the STAR-LLD group. Progression-free survival was also significantly increased in the continuous infusion group, STAR-LLD had the longest survival with two animals surviving to 100 days, where all animals treated with lenalidomide standard of care had failed treatment by day 52.
Starton is a clinical-stage biotechnology company transforming approved drugs for novel indications. Our initial focus is in hematological malignancies using a continuous delivery platform. Its blockbuster program, STAR-LLD is entering Phase 1/2 development for multiple new indications in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
The STAR-LLD program has already displayed unprecedented efficacy results in a murine multiple myeloma model. The STAR-LLD continuous infusion displayed superior efficacy versus lenalidomide standard of care: tumor volume increase at day 29 was 483% with standard of care versus an -81% reduction in tumor volume in the STAR-LLD group. Progression-free survival was also significantly increased in the continuous infusion group, STAR-LLD had the longest survival with two animals surviving to 100 days, where all animals treated with lenalidomide standard of care had failed treatment by day 52.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
STAR-OLZ (olanzapine)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
